Nov 4, 2021 08:00AM
Sep 8, 2021 09:20AM
Sep 8, 2021 08:08AM
Sep 8, 2021 06:05AM
Sep 8, 2021 01:00AM
Sep 8, 2021 01:00AM
Aug 19, 2021 04:01PM Kadmon Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
Aug 5, 2021 04:05PM
Aug 4, 2021 04:01PM
Jul 19, 2021 09:22AM
Jul 19, 2021 07:07AM
Jul 19, 2021 07:00AM
Jul 16, 2021 02:22PM
Jul 16, 2021 02:20PM U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
May 25, 2021 04:01PM
May 19, 2021 10:00PM
May 13, 2021 10:00PM
May 6, 2021 04:01PM
May 5, 2021 10:25PM
Apr 28, 2021 05:00PM
Apr 21, 2021 07:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Repro Med, SOS Limited, Canoo, and Kadmon Holdings and Encourages Investors to Contact the Firm
Apr 21, 2021 08:01AM
Apr 21, 2021 08:00AM
Apr 15, 2021 09:00AM
Apr 14, 2021 08:00PM
Apr 12, 2021 03:50PM
Apr 7, 2021 11:33AM
Apr 1, 2021 08:05AM Kadmon (KDMN) Reports First Patient Dosing in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis
Apr 1, 2021 08:00AM
Mar 11, 2021 09:28AM
Mar 10, 2021 05:39PM
Mar 10, 2021 04:16PM
Mar 10, 2021 04:14PM
Mar 4, 2021 04:01PM
Feb 23, 2021 04:05PM Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide
Dec 1, 2020 06:39AM
Nov 30, 2020 08:08AM
Nov 30, 2020 08:00AM
Nov 24, 2020 08:00AM
Nov 11, 2020 09:29AM
Nov 5, 2020 04:14PM
Nov 4, 2020 04:15PM Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting
Sep 30, 2020 04:20PM
Sep 30, 2020 04:14PM
Sep 8, 2020 08:00AM
Sep 4, 2020 03:01PM
Aug 13, 2020 04:50PM
Aug 13, 2020 04:15PM
Aug 6, 2020 04:14PM Kadmon Provides Business Update and Reports Second Quarter 2020 Financial Results
Jun 5, 2020 04:17PM

322,093 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All